Claims for Patent: 10,005,833

✉ Email this page to a colleague

Summary for Patent: 10,005,833

Title:	Methods of treating inflammation associated airway diseases and viral infections
Abstract:	The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
Inventor(s):	Bose; Santanu (Pullman, WA), Tessier; Philippe (Quebec, CA)
Assignee:	WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)
Application Number:	14/985,591
Patent Claims:	1. A method of treating a viral influenza lung pathogen infection by controlling inflammation in a subject without substantially affecting viral burden in the subject, said method comprising the steps of: i)administering an anti-S100A9 antibody to the subject in need of thereof; and ii) assessing the viral burden in the subject. 2. The method of claim 1, wherein the control of inflammation is a reduction in TNF-.alpha., a reduction in IL-6, or both. 3. The method of claim 1, wherein the control of inflammation is a reduction in TNF-.alpha.. 4. The method of claim 1, wherein the control of inflammation is a reduction in IL-6. 5. The method of claim 1, wherein the viral influenza lung pathogen is influenza A. 6. The method of claim 1, wherein the method further comprises administering a second therapeutic agent in conjunction with the anti-S100A9 antibody, wherein the second therapeutic agent is an antiviral drug. 7. The method of claim 6, wherein the second therapeutic agent is selected from the group consisting of amantadine, oseltamivir, zanamivir, ribavirin, and palivizumab. 8. The method of claim 1, wherein the anti-S100A9 antibody is administered to the subject via a route selected the group consisting of inhalation to the respiratory system, instillation in the respiratory system, intraperitoneal injection, and intravenous injection. 9. The method of claim 1, wherein the anti-S100A9 antibody is a humanized anti-S100A9 antibody. 10. The method of claim 1, wherein the anti-S100A9 antibody is S100A9-binding antibody fragment or an antibody conjugate. 11. The method of claim 1, wherein the anti-S100A9 antibody is S100A9-binding antibody fragment. 12. The method of claim 1, wherein the reduction of inflammation in the lung of the subject without affecting viral burden of the lung pathogen infection of the subject is present within 3 days of administration of the anti-S100A9 antibody to the subject.

Details for Patent 10,005,833

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	June 19, 1998	⤷ Subscribe	2035-01-02
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	July 23, 2004	⤷ Subscribe	2035-01-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.